A Phase I, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Intrathecal Infusion of KP-100IT through SM-1500 in Subjects with Amyotrophic Lateral Sclerosis (ALS).

Trial Profile

A Phase I, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Intrathecal Infusion of KP-100IT through SM-1500 in Subjects with Amyotrophic Lateral Sclerosis (ALS).

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Hepatocyte growth factor (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Kringle Pharma
  • Most Recent Events

    • 13 Jul 2015 Planned number of patients changed from 12 to 15 as per University Hospital Medical Information Network - Japan.
    • 11 Mar 2015 According to Kringle Pharm media release, status changed from active, no longer recruiting to completed.
    • 16 Jun 2014 Status changed from recruiting to active, no longer recruiting according to the Kingle Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top